Postoperative Cognitive DysfunctionBM-POCDNCT03610191
MD2, Cystatin C and DNA Methylation Tags as Serum Biomarkers for POCD.
An observational study of Postoperative Cognitive Dysfunction, run by Xijing Hospital at 1 site in China.
Trial summary
Postoperative cognitive dysfunction (POCD) is a severe complication after surgery. Currently, a complicated battery of neuropsychological tests both before and after surgery with other characteristics-matched population as control are needed for the diagnosis of POCD. Read more about this study
- Who is it for?
- Ages 18 to 108 years
- Conditions the study is for
- Postoperative Cognitive Dysfunction
- What is being tested?
- Serum biomarker tests, Neuropsychological battery tests and Cardiac surgery
- Type of treatment
- Surgery or procedure, Lifestyle or therapy programme
- How many people
- 250 participants
- Where
- 1 siteChina
- Study dates
- 20 Nov 2018to 1 Dec 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 108 years
- All sexes
- Adult, Older adult
Study population: Patients undergoing cardiac surgery under cardio-pulmonary bypass (CPB) and general anesthesia. Non-surgical controls are age and gender-matched community residents.
Who may be able to join
- Patients age≥18 yrs scheduled for coronary artery bypass graft (CABG), valve replacement or CABG+valve replacement surgery under CPB and general anesthesia in Xijing Hospital, from Nov, 2018.
Who cannot join
- Has neurodegenerative disease: dementia, Alzheimer's or Parkinson's Disease
- Has received neuropsychological tests before
- Psychological disorder that needs medication
- Preoperative Mini-Mental State Examination (MMSE)< 24
- Didn't finish elementary school
- Has symptomatic cerebrovascular disease.
Show all 16Show fewer
- Has received cardiac surgery or neurosurgery before
- Has cardiac arrest experience and received cardiopulmonary resuscitation
- Renal dysfunction (serum creatinine>2 mg/dL or 176.82 μmol/L)
- Hepatic pathology (AST, ALT exceeded 1.5 times of the upper limit of normal range)
- Unable to comply or non-cooperative
- Can't finish process under instruction
- Can't understand mandarin
- Has severe visual or auditorial impairment
- Has severe alcohol or drug dependence (has been drinking over 100 ml of ≥50° alcohol per day , for over 3 months. And other drug abuse problem)
- Has been enrolled in the same study before or is currently involved in other clinical trials.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Xijing Hospital
Xi'an, Shaanxi, 710032
Jing Zhao, M.D., 13892810471
Lihong Hou, M.D., Ph.D., +862984775337
About this study
Official title: Serum Biomarkers for Prediction and Diagnosis of POCD in Elderly Patients Undergoing Cardiac Surgery.
Postoperative cognitive dysfunction (POCD) is a severe complication after surgery. Currently, a complicated battery of neuropsychological tests both before and after surgery with other characteristics-matched population as control are needed for the diagnosis of POCD. This diagnosis is also delayed, which could not be used to screen for high risk patients who may need intervention beforehand. The current trial targeted a surgical population of elderly patients undergoing cardiac surgery under cardiopulmonary bypass (CPB), which is a population of the highest incidence of POCD, to screen for possible predictive or diagnostic biomarkers in the serum for POCD. Myeloid differentiation factor 2 (MD2), also known as lymphocyte antigen 96, is a protein involved in biding lipopolysaccharide with Toll like receptor-4 (TLR4). Recently the investigators have found that increased MD2 expression in the hippocampus of the mice after surgery stimuli. On the other hand, the investigators have reported that cystatin C (CysC) as an endogenous neuroprotective factor for stroke. It may also be involved in endogenous neural protection against POCD. This trial is to investigate whether serum MD2, CysC can be used for prediction and diagnosis of POCD in surgical population. Serum based DNA methylation biomarkers will also be tested for prediction or diagnosis of POCD development. Also in our orevious research, SNPs cites at rs6739405、rs12467815、rs12472215、rs11126727、rs11126731、rs993607 were revealed as possible susceptibility variations for POCD (diagnosed with MMSE only, NCT02084030) in patients undergoing CPB. This study will also test the SNP variations in study populations to varify if one or conbination of morethan one of these varuations can be a risk factor for POCD when diagonosed with NPT.
Read the detailed description
Postoperative cognitive dysfunction (POCD) is a common complication of surgical patients, which manifested by reduced memory, attention and calculation abilities etc. Among different types of surgeries, the incidence of POCD in cardiac surgical patients are the highest, the prevalence of POCD on the day of discharge was as high as 53%, and 26% of patients still showed cognitive dysfunction three months after surgery. POCD can increase patients' hospitalization days, increase the consumption of medical resources and social security resources, seriously affect patients' postoperative quality of life, and even increase the mortality rate one year after surgery. There is no definite serum marker for the prediction and diagnosis of POCD. The diagnosis currently applied are a series of neuropsychological battery tests both before and after surgery. it's both time consuming and inapplicable to patients in severe conditions. The purpose of this trial is to screen out POCD serum markers as effective indicators for POCD prediction, early diagnosis of POCD, and assessment for therapeutic efficacy.
At present, the pathogenesis of POCD is not clear. Aging, general anesthesia, heart surgery, preoperative cognitive impairment and cardiovascular diseases are high risk factors for POCD. At present, preoperative and postoperative neuropsychological behavior assessments is the only way to diagnose POCD, but it is time consuming, resource occupying, and also has learning effect. However, studies on serum markers that can predict the risk of POCD or for early diagnosis of POCD are still at a very preliminary stage. Study has found that plasma inflammatory factors: interleukin (IL)-1β, IL-8 and tumor necrosis factor-α level raised in POCD patients [1-2]. In addition, in microglial cells, inflammatory reaction mediated by S100β modulated the receptor for advanced glycation end products (RAGE) signaling pathway [3], and raise pro-inflammatory factor expressions [4], so S100β expression may be related to POCD occurrence. However, inflammatory related factors such as IL-1, IL-8 and TNF-α lack neurological or disease specificity. S100B, previously thought to have diagnostic effects of nerve injury, has not been confirmed in small sample correlation studies [5]. Therefore, it is of great clinical significance to collect reliable and powerful clinical research data to explore serum biomarkers for early prediction and diagnosis of POCD.
The investigators have previously found that higher endogenous CystatinC level is an important protective mechanism against ischemic brain injury. Elevated serum Cystatin C, accompanied with brain cystatin C level elevation, can inhibit lysosome damage, promote autophagy [6] and induce ischemic tolerance in the brain. Myeloid differentiation protein (MD-2) is a secreted protein, composed of 160 amino acids and participate in TLR4 signaling pathway, mediated inflammatory response [7]. The investigator using an animal model of POCD also found that the MD2 expression is significantly increased after surgery.
In addition, the methylation is an important modification way of proteins and nucleic acids, it regulates the expression of genes and is closely related to many diseases such as alzheimer's. Studies have shown that COASY and SPINT1[17], NCAPH2/LMF2[18] promoter region DNA methylation has diagnostic value for alzheimer's disease and mild cognitive impairment. Therefore, we speculate that changes in the DNA methylation markers of the central nervous system may be of early diagnostic value for POCD after cardiac surgery. Therefore, the detection of the central nervous system methylation label in the serum of patients after cardiac surgery will provide a new research direction for the clinical detection of central nervous system injury.
Our previous clinical trial (NCT 02084030) indicates that, 6 SNP mutations on the CTNNA2 gene (SNPs cites at rs6739405、rs12467815、rs12472215、rs11126727、rs11126731、rs993607) has altered risk for POCD in elderly patients undergoing CPB. Since this gene functions as a linker between cadherin adhesion receptors and the cytoskeleton to regulate cell-cell adhesion and differentiation in the nervous system, it also regulates morphological plasticity of synapses and cerebellar and hippocampal lamination during development, we aim to verify if patients that has any of these mutations is more susceptible to POCD then patients that has none, or less of these mutations, using a more integrated neuropsychological test battery tests as compared to MMSE used in the previous trial.
In conclusion, the investigators believe that serum central nerveous system (CNS) specific methylation markers, MD2 level and CystatinC level may have predictive and diagnostic value for POCD. This trial is to to evaluate POCD in 200 patients with cardiac surgery under CPB, test their perioperative serum MD2, CystatinC, and DNA methylation markers from the central nervous system, and explore their role in prediction and diagnosis of POCD.
- Conditions
- Postoperative Cognitive Dysfunction
- Being tested
- Serum biomarker tests, Neuropsychological battery tests, Cardiac surgery
- Keywords
- biomarkers, MD2, Cystatin C, DNA methylation markers, SNP mutations in CTNNA2 gene
- Medical subject headings
- Postoperative Cognitive Complications
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Serum biomarker testsDiagnostic test
Blood was collected at preoperatively, immediately after operation and 24 h after operation in patients from the surgical group but not volunteers. Serum MD2, CysC, DNA methylation marker and SNP mutation sites on CTNNA2 gene were test.
Neuropsychological battery testsBehavioural
Also called NPB tests
both surgical patients and volunteers will accept three times of NPB tests. For surgical patients the tested time point are preoperative, one day before discharge and 3 months after surgery. For volunteers the tested time interval would be similar to that of surgical patients.
Cardiac surgeryProcedure or surgery
patients scheduled for cardiac surgery will accept the surgical procedure.
| Study group | Role | What they receive |
|---|---|---|
| Surgery | Patients aged over 18 scheduled for elective cardiac surgery under CPB and general anesthesia. This group will later be divided in to two sub groups based on their neuropsychological battery tests results before surgery and one day before discharge. Blood sample will be collected before, immediately after surgery and at 24h after surgery for serum biomarker tests: MD2, CysC as well as DNA methylation markers of neural system origin. Receives: Diagnostic Test: Serum biomarker tests; Behavioral: Neuropsychological battery tests; Procedure: Cardiac surgery | |
| non-surgical control | Age and sex matched volunteers from the community were included for neuropsychological battery tests and set as controls for the diagnosis of POCd in surgical patients. Receives: Behavioral: Neuropsychological battery tests |
What is being measured
The primary outcome is the main question the study is designed to answer.
Preoperative serum MD2/CysC/DAN Methylation marker/SNPs mutation rates on CTNNA2 gene before anesthesia
Blood samples will be collected at immediately before anesthesia and tested for MD2/CysC/DAN Methylation marker value.
Measured: Immediately before anesthesia
Postoperative serum MD2/CysC/DAN Methylation marker/immediately after surgery
Blood samples will be collected at immediately after surgery and tested for MD2/CysC/DAN Methylation marker value.
Measured: Immediately after surgery
Postoperative serum MD2/CysC/DAN Methylation marker value at 24 h after surgery
Blood samples will be collected at 24h after surgery and tested for MD2/CysC/DAN Methylation marker value.
Measured: Twenty-four hours after surgery
Neuropsychological battery (NPB) assessment
NPB will be evaluated at 3 time points: 1. one day before surgery. 2. one day before discharge. 3. 3 months after surgery. The NPB includes: 1. Grooved Pegboard Test; 2. Auditory Word Memory Test; 3. Trail Making Test (Part A, Part B); 4. Digit Span Test; 5. Digit Symbol Subtest; 6. Verbal Fluency Test; and 7. Word Recall Test.
POCD at discharge or 3 months after surgery will be analyzed as follow: 2 or more tests of the NPB with a Z score over 1.96 or less than -1.96, patient is defined as POCD. And patients that have less than 2 tests with a Z score over 1.96 is defined as no-POCD.
Note: the time frame of postoperative NPB test is defined as one day before discharge. It is usually within 5-9 days depending on the hospitalization time for each patient. Since NPB test is time consuming and requires patients at a comfortable state. The investigators chose one day before discharge as many clinical trials regarding POCD reported.
Measured: From one day before surgery to 3 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Aug 2018
- Study start20 Nov 2018
- Primary completion1 Sep 2021 (estimated)
- Study completion1 Dec 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Postoperative Cognitive DysfunctionStudies of the same condition, open and under way.
- More trials run by Xijing HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 250 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xijing Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Lize Xiong, Xijing Hospital
- Investigators
- Lize Xiong, M.D., Ph.D., Principal investigator, Xijing Hospital, the Fourth Military Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03610191
- Sponsor's protocol ID
- KY20182029-1
- Acronym
- BM-POCD
- Status last verified
- Jul 2020
- First submitted
- 3 Jul 2018
- Last updated
- 7 Jul 2020
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Li YC, Xi CH, An YF, Dong WH, Zhou M. Perioperative inflammatory response and protein S-100beta concentrations - relationship with post-operative cognitive dysfunction in elderly patients. Acta Anaesthesiol Scand. 2012 May;56(5):595-600. doi: 10.1111/j.1399-6576.2011.02616.x. Epub 2012 Jan 9.
PubMed 22224444Bi Y, Liu S, Yu X, Wu M, Wang Y. Adaptive and regulatory mechanisms in aged rats with postoperative cognitive dysfunction. Neural Regen Res. 2014 Mar 1;9(5):534-9. doi: 10.4103/1673-5374.130084.
PubMed 25206851Bianchi R, Adami C, Giambanco I, Donato R. S100B binding to RAGE in microglia stimulates COX-2 expression. J Leukoc Biol. 2007 Jan;81(1):108-18. doi: 10.1189/jlb.0306198. Epub 2006 Oct 5.
PubMed 17023559Li RL, Zhang ZZ, Peng M, Wu Y, Zhang JJ, Wang CY, Wang YL. Postoperative impairment of cognitive function in old mice: a possible role for neuroinflammation mediated by HMGB1, S100B, and RAGE. J Surg Res. 2013 Dec;185(2):815-24. doi: 10.1016/j.jss.2013.06.043. Epub 2013 Jul 17.
PubMed 23899512Linstedt U, Meyer O, Kropp P, Berkau A, Tapp E, Zenz M. Serum concentration of S-100 protein in assessment of cognitive dysfunction after general anesthesia in different types of surgery. Acta Anaesthesiol Scand. 2002 Apr;46(4):384-9. doi: 10.1034/j.1399-6576.2002.460409.x.
PubMed 11952437Fang Z, Deng J, Wu Z, Dong B, Wang S, Chen X, Nie H, Dong H, Xiong L. Cystatin C Is a Crucial Endogenous Protective Determinant Against Stroke. Stroke. 2017 Feb;48(2):436-444. doi: 10.1161/STROKEAHA.116.014975. Epub 2016 Dec 20.
PubMed 27999137Kobayashi N, Shinagawa S, Nagata T, Shimada K, Shibata N, Ohnuma T, Kasanuki K, Arai H, Yamada H, Nakayama K, Kondo K. Usefulness of DNA Methylation Levels in COASY and SPINT1 Gene Promoter Regions as Biomarkers in Diagnosis of Alzheimer's Disease and Amnestic Mild Cognitive Impairment. PLoS One. 2016 Dec 19;11(12):e0168816. doi: 10.1371/journal.pone.0168816. eCollection 2016.
PubMed 27992572
Study at a glance
From the registry record, last updated by the sponsor on 7 Jul 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Serum Biomarkers for Prediction and Diagnosis of POCD in Elderly Patients Undergoing Cardiac Surgery.
- ClinicalTrials.gov ID
- NCT03610191
- Acronym / sponsor ID
- BM-POCD / KY20182029-1
- Conditions
- Postoperative Cognitive Dysfunction
- Keywords
- biomarkers, MD2, Cystatin C, DNA methylation markers, SNP mutations in CTNNA2 gene
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 250 participants (estimated)
- Lead sponsor
- Xijing HospitalUniversity, hospital or other
- Study start
- 20 Nov 2018 (actual)
- Primary completion
- 1 Sep 2021 (estimated)
- Study completion
- 1 Dec 2021 (estimated)
- First posted
- 1 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Postoperative cognitive dysfunction (POCD) is a severe complication after surgery. Currently, a complicated battery of neuropsychological tests both before and after surgery with other characteristics-matched population as control are needed for the diagnosis of POCD. This diagnosis is also delayed, which could not be used to screen for high risk patients who may need intervention beforehand. The current trial targeted a surgical population of elderly patients undergoing cardiac surgery under cardiopulmonary bypass (CPB), which is a population of the highest incidence of POCD, to screen for possible predictive or diagnostic biomarkers in the serum for POCD. Myeloid differentiation factor 2 (MD2), also known as lymphocyte antigen 96, is a protein involved in biding lipopolysaccharide with Toll like receptor-4 (TLR4). Recently the investigators have found that increased MD2 expression in the hippocampus of the mice after surgery stimuli. On the other hand, the investigators have reported that cystatin C (CysC) as an endogenous neuroprotective factor for stroke. It may also be involved in endogenous neural protection against POCD. This trial is to investigate whether serum MD2, CysC can be used for prediction and diagnosis of POCD in surgical population. Serum based DNA methylation biomarkers will also be tested for prediction or diagnosis of POCD development. Also in our orevious research, SNPs cites at rs6739405、rs12467815、rs12472215、rs11126727、rs11126731、rs993607 were revealed as possible susceptibility variations for POCD (diagnosed with MMSE only, NCT02084030) in patients undergoing CPB. This study will also test the SNP variations in study populations to varify if one or conbination of morethan one of these varuations can be a risk factor for POCD when diagonosed with NPT.
Detailed description
Postoperative cognitive dysfunction (POCD) is a common complication of surgical patients, which manifested by reduced memory, attention and calculation abilities etc. Among different types of surgeries, the incidence of POCD in cardiac surgical patients are the highest, the prevalence of POCD on the day of discharge was as high as 53%, and 26% of patients still showed cognitive dysfunction three months after surgery. POCD can increase patients' hospitalization days, increase the consumption of medical resources and social security resources, seriously affect patients' postoperative quality of life, and even increase the mortality rate one year after surgery. There is no definite serum marker for the prediction and diagnosis of POCD. The diagnosis currently applied are a series of neuropsychological battery tests both before and after surgery. it's both time consuming and inapplicable to patients in severe conditions. The purpose of this trial is to screen out POCD serum markers as effective indicators for POCD prediction, early diagnosis of POCD, and assessment for therapeutic efficacy.
At present, the pathogenesis of POCD is not clear. Aging, general anesthesia, heart surgery, preoperative cognitive impairment and cardiovascular diseases are high risk factors for POCD. At present, preoperative and postoperative neuropsychological behavior assessments is the only way to diagnose POCD, but it is time consuming, resource occupying, and also has learning effect. However, studies on serum markers that can predict the risk of POCD or for early diagnosis of POCD are still at a very preliminary stage. Study has found that plasma inflammatory factors: interleukin (IL)-1β, IL-8 and tumor necrosis factor-α level raised in POCD patients [1-2]. In addition, in microglial cells, inflammatory reaction mediated by S100β modulated the receptor for advanced glycation end products (RAGE) signaling pathway [3], and raise pro-inflammatory factor expressions [4], so S100β expression may be related to POCD occurrence. However, inflammatory related factors such as IL-1, IL-8 and TNF-α lack neurological or disease specificity. S100B, previously thought to have diagnostic effects of nerve injury, has not been confirmed in small sample correlation studies [5]. Therefore, it is of great clinical significance to collect reliable and powerful clinical research data to explore serum biomarkers for early prediction and diagnosis of POCD.
The investigators have previously found that higher endogenous CystatinC level is an important protective mechanism against ischemic brain injury. Elevated serum Cystatin C, accompanied with brain cystatin C level elevation, can inhibit lysosome damage, promote autophagy [6] and induce ischemic tolerance in the brain. Myeloid differentiation protein (MD-2) is a secreted protein, composed of 160 amino acids and participate in TLR4 signaling pathway, mediated inflammatory response [7]. The investigator using an animal model of POCD also found that the MD2 expression is significantly increased after surgery.
In addition, the methylation is an important modification way of proteins and nucleic acids, it regulates the expression of genes and is closely related to many diseases such as alzheimer's. Studies have shown that COASY and SPINT1[17], NCAPH2/LMF2[18] promoter region DNA methylation has diagnostic value for alzheimer's disease and mild cognitive impairment. Therefore, we speculate that changes in the DNA methylation markers of the central nervous system may be of early diagnostic value for POCD after cardiac surgery. Therefore, the detection of the central nervous system methylation label in the serum of patients after cardiac surgery will provide a new research direction for the clinical detection of central nervous system injury.
Our previous clinical trial (NCT 02084030) indicates that, 6 SNP mutations on the CTNNA2 gene (SNPs cites at rs6739405、rs12467815、rs12472215、rs11126727、rs11126731、rs993607) has altered risk for POCD in elderly patients undergoing CPB. Since this gene functions as a linker between cadherin adhesion receptors and the cytoskeleton to regulate cell-cell adhesion and differentiation in the nervous system, it also regulates morphological plasticity of synapses and cerebellar and hippocampal lamination during development, we aim to verify if patients that has any of these mutations is more susceptible to POCD then patients that has none, or less of these mutations, using a more integrated neuropsychological test battery tests as compared to MMSE used in the previous trial.
In conclusion, the investigators believe that serum central nerveous system (CNS) specific methylation markers, MD2 level and CystatinC level may have predictive and diagnostic value for POCD. This trial is to to evaluate POCD in 200 patients with cardiac surgery under CPB, test their perioperative serum MD2, CystatinC, and DNA methylation markers from the central nervous system, and explore their role in prediction and diagnosis of POCD.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Surgery | – | Diagnostic Test: Serum biomarker tests, Behavioral: Neuropsychological battery tests, Procedure: Cardiac surgeryPatients aged over 18 scheduled for elective cardiac surgery under CPB and general anesthesia. This group will later be divided in to two sub groups based on their neuropsychological battery tests results before surgery and one day before discharge. Blood sample will be collected before, immediately after surgery and at 24h after surgery for serum biomarker tests: MD2, CysC as well as DNA methylation markers of neural system origin. |
| non-surgical control | – | Behavioral: Neuropsychological battery testsAge and sex matched volunteers from the community were included for neuropsychological battery tests and set as controls for the diagnosis of POCd in surgical patients. |
Who may qualify
- Ages
- 18 to 108 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients undergoing cardiac surgery under cardio-pulmonary bypass (CPB) and general anesthesia. Non-surgical controls are age and gender-matched community residents.
Key inclusion criteria (1 listed)
- Patients age≥18 yrs scheduled for coronary artery bypass graft (CABG), valve replacement or CABG+valve replacement surgery under CPB and general anesthesia in Xijing Hospital, from Nov, 2018.
Key exclusion criteria (16 listed)
- Has neurodegenerative disease: dementia, Alzheimer's or Parkinson's Disease
- Has received neuropsychological tests before
- Psychological disorder that needs medication
- Preoperative Mini-Mental State Examination (MMSE)< 24
- Didn't finish elementary school
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Serum biomarker testsBlood was collected at preoperatively, immediately after operation and 24 h after operation in patients from the surgical group but not volunteers. Serum MD2, CysC, DNA methylation marker and SNP mutation sites on CTNNA2 gene were test. | Diagnostic test | Surgery |
| Neuropsychological battery testsAlso: NPB testsboth surgical patients and volunteers will accept three times of NPB tests. For surgical patients the tested time point are preoperative, one day before discharge and 3 months after surgery. For volunteers the tested time interval would be similar to that of surgical patients. | Behavioural | Surgery, non-surgical control |
| Cardiac surgerypatients scheduled for cardiac surgery will accept the surgical procedure. | Procedure or surgery | Surgery |
Primary outcome
Preoperative serum MD2/CysC/DAN Methylation marker/SNPs mutation rates on CTNNA2 gene before anesthesia
Time frame: Immediately before anesthesia
Blood samples will be collected at immediately before anesthesia and tested for MD2/CysC/DAN Methylation marker value.
Postoperative serum MD2/CysC/DAN Methylation marker/immediately after surgery
Time frame: Immediately after surgery
Blood samples will be collected at immediately after surgery and tested for MD2/CysC/DAN Methylation marker value.
Postoperative serum MD2/CysC/DAN Methylation marker value at 24 h after surgery
Time frame: Twenty-four hours after surgery
Blood samples will be collected at 24h after surgery and tested for MD2/CysC/DAN Methylation marker value.
Neuropsychological battery (NPB) assessment
Time frame: From one day before surgery to 3 months after surgery
NPB will be evaluated at 3 time points: 1. one day before surgery. 2. one day before discharge. 3. 3 months after surgery. The NPB includes: 1. Grooved Pegboard Test; 2. Auditory Word Memory Test; 3. Trail Making Test (Part A, Part B); 4. Digit Span Test; 5. Digit Symbol Subtest; 6. Verbal Fluency Test; and 7. Word Recall Test. POCD at discharge or 3 months after surgery will be analyzed as follow: 2 or more tests of the NPB with a Z score over 1.96 or less than -1.96, patient is defined as POCD. And patients that have less than 2 tests with a Z score over 1.96 is defined as no-POCD. Note: the time frame of postoperative NPB test is defined as one day before discharge. It is usually within 5-9 days depending on the hospitalization time for each patient. Since NPB test is time consuming and requires patients at a comfortable state. The investigators chose one day before discharge as many clinical trials regarding POCD reported.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2020.
- Background: PubMed 22224444Li YC, Xi CH, An YF, Dong WH, Zhou M. Perioperative inflammatory response and protein S-100beta concentrations - relationship with post-operative cognitive dysfunction in elderly patients. Acta Anaesthesiol Scand. 2012 May;56(5):595-600. doi: 10.1111/j.1399-6576.2011.02616.x. Epub 2012 Jan 9.
- Background: PubMed 25206851Bi Y, Liu S, Yu X, Wu M, Wang Y. Adaptive and regulatory mechanisms in aged rats with postoperative cognitive dysfunction. Neural Regen Res. 2014 Mar 1;9(5):534-9. doi: 10.4103/1673-5374.130084.
- Background: PubMed 17023559Bianchi R, Adami C, Giambanco I, Donato R. S100B binding to RAGE in microglia stimulates COX-2 expression. J Leukoc Biol. 2007 Jan;81(1):108-18. doi: 10.1189/jlb.0306198. Epub 2006 Oct 5.
- Background: PubMed 23899512Li RL, Zhang ZZ, Peng M, Wu Y, Zhang JJ, Wang CY, Wang YL. Postoperative impairment of cognitive function in old mice: a possible role for neuroinflammation mediated by HMGB1, S100B, and RAGE. J Surg Res. 2013 Dec;185(2):815-24. doi: 10.1016/j.jss.2013.06.043. Epub 2013 Jul 17.
- Background: PubMed 11952437Linstedt U, Meyer O, Kropp P, Berkau A, Tapp E, Zenz M. Serum concentration of S-100 protein in assessment of cognitive dysfunction after general anesthesia in different types of surgery. Acta Anaesthesiol Scand. 2002 Apr;46(4):384-9. doi: 10.1034/j.1399-6576.2002.460409.x.
- Background: PubMed 27999137Fang Z, Deng J, Wu Z, Dong B, Wang S, Chen X, Nie H, Dong H, Xiong L. Cystatin C Is a Crucial Endogenous Protective Determinant Against Stroke. Stroke. 2017 Feb;48(2):436-444. doi: 10.1161/STROKEAHA.116.014975. Epub 2016 Dec 20.
- Background: PubMed 27992572Kobayashi N, Shinagawa S, Nagata T, Shimada K, Shibata N, Ohnuma T, Kasanuki K, Arai H, Yamada H, Nakayama K, Kondo K. Usefulness of DNA Methylation Levels in COASY and SPINT1 Gene Promoter Regions as Biomarkers in Diagnosis of Alzheimer's Disease and Amnestic Mild Cognitive Impairment. PLoS One. 2016 Dec 19;11(12):e0168816. doi: 10.1371/journal.pone.0168816. eCollection 2016.
Related trials for Postoperative Cognitive Dysfunction
Not yet recruiting
Prediction and Prevention of Postoperative Mortality and Morbidity
Dementia, Postoperative Delirium (POD)
Active, not recruitingObservational study
Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor
Cognitive Decline, Urinary Bladder Cancer
Active, not recruitingObservational study
The Effect of Single Lung Ventilation Duration and Intraoperative Brain Oxygenation on Cognitive Function and Postoperative Pain in Geriatric Patients
Thoracic Anesthesia, Geriatric Anesthesia
Not yet recruitingPhase 4
Effects of Remimazolam on Postoperative Cognitive Dysfunction and Neuroinflammatory Biomarkers in Patients Undergoing Aortic Arch Surgery
Aortic Aneurysm of the Proximal Arch, Aortic Aneurysms Arch
Enrolling by invitationPhase 4
Effects of Ciprofol on Perioperative Neurocognitive Function in Elderly Patients Undergoing Daytime Surgery
PND, POCD - Postoperative Cognitive Dysfunction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lize Xiong, M.D., Ph.D. principal investigator
Xijing Hospital, the Fourth Military Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Postoperative Cognitive Dysfunction, run by Xijing Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 7 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Jiao Deng, M.D., Ph.D. (+8615929779202, peazi@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Preoperative serum MD2/CysC/DAN Methylation marker/SNPs mutation rates on CTNNA2 gene before anesthesia (time frame: Immediately before anesthesia). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03610191, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2020.